摘要
探讨IFN-α、胸腺肽联合利巴韦林治疗抗-HBe阳性的慢性乙型肝炎疗效。抗-HBe阳性的慢性乙型肝炎72例,随机分为两组,A组为治疗组,使用α-1b干扰素(赛若金)、胸腺肽和利巴韦林治疗。B组为对照组,给α-1b干扰素(赛若金)和胸腺肽治疗。A组治疗12个月,随访6个月、12个月时肝功能复常率及HBV-DNA转阴率分别是72.2％、75％;61.1％、63.9％和55.6％、58.3％,效果显著。与对照组相比,HBV-DNA阴转率存在显著性差异;肝功能复常率在治疗结束时无显著差异,随访12个月时差异显著。IFN-α、胸腺肽联合利巴韦林治疗抗-HBe阳性的慢性乙型肝炎疗效显著,副反应低,值得进一步研究和应用。
To explore the efficacy of interferon-α, thymus peptide combined with ribavirin on antihepatitig B e- positive chronic hepatitis B. 72 cases with anti - hepatitis B e- positive chronic hepatitis B were randomly divided into two groups. Group A was given interferon - α, thymus peptide combined with ribavirin. Group B was given interferon - α and thymus peptide. The value of ALT, serologic markers of HBV- DNA were detected respectively before and after treatment. At the end of treatment, the ALT normalization rate and the HBV - DNA seroconversion rate of group A were 72.2% ,75%. Those of group B were 52.8%, 41.7%. There were no significantly difference in the ALT normalization rate between group A and group B, but in the HBV -DNA seroconversion rate there were significantly difference. Follow up 6 mouths and 12 mouths, the ALT normalization rate and the HBV - DNA seroconversion rate of group A were 61.1 %, 55.6% and 63.9%, 58.3% respectively. Those of group B were 41.7% , 27.8% and 33.3% ,22.2%, respectively. There were significantly difference in the HBV - DNA seroconversion rate and the ALT normalization rate follow up 12 mouths between group A and group B. interferon- α,thymus peptide combined with ribavirin on anti - hepatitis B e- positive chronic hepatitis B is more effective.
出处
《临床肝胆病杂志》
CAS
北大核心
2003年第5期294-295,共2页
Journal of Clinical Hepatology
